Publication
and Prognosis in mCRPC Survival: Biology or Coincidence?
Journal Paper/Review - Jan 4, 2019
Rebello Richard J, Oing Christoph, Gillessen Sommer Silke, Bristow Robert G
Units
PubMed
Doi
Citation
Type
Journal
Publication Date
Issn Print
Pages
Brief description/objective
Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al., p. 1766.